Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.

Autor: Kovács Á; Department of Biochemistry and Molecular Biology, University of Szeged, Szeged, Hungary., Sükösd F; Department of Pathology, University of Szeged, Szeged, Hungary., Kuthi L; Department of Pathology, University of Szeged, Szeged, Hungary., Boros IM; Department of Biochemistry and Molecular Biology, University of Szeged, Szeged, Hungary. borosi@bio.u-szeged.hu.; Hungarian Research Network Biological Research Center, Institute of Biochemistry, Szeged, Hungary. borosi@bio.u-szeged.hu., Vedelek B; Department of Biochemistry and Molecular Biology, University of Szeged, Szeged, Hungary. vedelekb@brc.hu.; Hungarian Research Network Biological Research Center, Institute of Genetics, Szeged, Hungary. vedelekb@brc.hu.
Jazyk: angličtina
Zdroj: Clinical and experimental medicine [Clin Exp Med] 2024 Aug 14; Vol. 24 (1), pp. 192. Date of Electronic Publication: 2024 Aug 14.
DOI: 10.1007/s10238-024-01464-3
Abstrakt: Telomerase reverse transcriptase promoter (TERTp) mutations are frequently targeted tumor markers, however, they reside in regions with high GC content, which poses challenges when examined with simple molecular techniques or even with next-generation sequencing (NGS). In bladder cancer (BC), TERTp mutations are particularly frequent, however, none of the available tools have demonstrated efficacy in detecting TERTp mutations via a simple noninvasive technique. Therefore, we developed a novel PCR-based method for the detection of the two most common TERTp mutations and demonstrated its use for the analysis of BC samples. The developed SHARD-PCR TERTp mutation detection technique requires PCR and restriction digestion steps that are easily implementable even in less well-equipped laboratories. Cell lines with known mutational status were utilized for method development. Matching urine and tumor tissue samples from BC patients were analyzed, and the results were validated by next-generation sequencing. Analysis of eighteen urine and corresponding tumor tissue samples by SHARD-PCR revealed perfect matches in sample pairs, which paralleled the corresponding NGS results: fourteen samples exhibited mutations at the -124 position, two samples showed mutations at the -146 position, and no mutations were detected in two samples. Our study serves as a proof-of-concept and is limited by its small sample size, nonetheless, it demonstrates that SHARD-PCR is a simple, economic and highly reliable method for detecting TERTp mutations, which are common in different cancer types. For bladder cancer, SHARD-PCR can be performed with the use of noninvasive samples and could replace or complement currently used techniques.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: